Skip links

Author: oncologs.com

msk-research-highlights,-may-24,-2024

MSK Research Highlights, May 24, 2024

New research from Memorial Sloan Kettering Cancer Center (MSK) investigates a promising approach against diabetic retinopathy and finds patients with early-onset colorectal cancer likely don’t need more frequent surveillance colonoscopies. Credit: Memorial Sloan Kettering Cancer Center New research from Memorial Sloan Kettering Cancer Center (MSK)
new-advances-in-cancer-viral-immunotherapy

New advances in cancer viral immunotherapy

Vaccinia viruses are therapeutic tools with different biomedical applications depending on the susceptibility characteristics. For example, the strain called MVA (modified vaccinia Ankara), which is unable to replicate in mammalian cells, triggers a potent immune system response and is used to develop vaccines against COVID-19
quadruple-therapies-and-the-future-of-multiple-myeloma-treatment

Quadruple therapies and the future of multiple myeloma treatment

MIAMI, FLORIDA (MAY 23, 2024) – The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent. Credit: Photo by Sylvester MIAMI, FLORIDA
new-biomarkers-of-response-in-melanoma-immunotherapy

New biomarkers of response in melanoma immunotherapy

Collagen, a major component of the extracellular matrix, plays a crucial role in tumor development. During the development of tumors (“tumorigenesis”), collagen fibers become linearized and densely deposited, hindering immune cell infiltration and promoting tumor metastasis. However, quantifying these collagen changes during melanoma progression has
Explore
Drag